TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03370887

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for AZ8601 injection for solution will be given as 30 injections per patient on a single occasion
Study: NCT04445818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: More appreciation

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Less criticism

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: More Fruit and Vegetable
Study: NCT00784043

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant
Description: Bilateral Implantation in children

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear Implant
Description: Bilateral Implantation in children
Study: NCT03487835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No application
Description: This group have no application during study time
Study: NCT01357798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0,9% saline
Description: 0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
Study: NCT03793985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T
Description: CKD-391 40/10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: T
Description: CKD-391 40/10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R
Description: D086 and D337 co-administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R
Description: D086 and D337 co-administration
Study: NCT02116634

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stem cell
Description: intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
Study: NCT04003649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Description: Given ITV/ITC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Description: Given ITV/ITC
Study: NCT00593138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dex-methylphenidate
Description: The drug is administered as a capsule by mouth. Participants are assigned to receive either 20, 30 or 40 mg doses before each scan visit.
Study: NCT01681043

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: protocol 'Quiet in the room'
Description: Protocol 'Quite in the room' between 10 p.m. and 6 a.m.~* nurse nearby~* no visits after 10 p.m.~* decreased alarm sound in ventilator and monitor~* decreased light intensity~* no unnecessary conversations around the patient~* medication should be limited to max 1-2 times in this time period~* no unnecessary therapeutic or diagnostic procedures in this time period~* earplugs and sleep masks
Study: NCT04003649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
Description: Given ITV/ITC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01440478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally
Study: NCT03610204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buffalo horn technique
Description: The participants receive a 30-min massage session, twice a week for a total 6 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Buffalo horn technique
Description: The participants receive a 30-min massage session, twice a week for a total 6 sessions.
Study: NCT03862313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active-rtACS treatment
Description: For the active-rtACS treatment arm, a CE-certificated proprietary class IIa medical device will be used to apply transorbital symmetrical rectangular current pulses in bursts (NextWave® 1.1 system; EBS Technologies GmbH, Germany). The stimulation protocol will be patient-individualized, with a stimulation current strength of 125% of the phosphene threshold recorded during 5Hz stimulation and stimulation frequencies between the individual's EEG alpha frequency and their flicker fusion frequency.
Study: NCT01440478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammonium chloride
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Administered orally
Study: NCT00879970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: Pioglitazone30 mg and 45 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosiglitazone
Description: Rosiglitazone 4 mg and 8 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo to match is Swedish orange size DB-AA capsule filled with white to off-white non-active powder blend.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D factor intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vitamin D factor intervention
Study: NCT00592020

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short Transverse Incision
Description: Short Transverse Incision for kidney transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hockey Stick Incision
Description: Hockey Stick Incision for kidney transplantation
Study: NCT03295058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non ATG Conditioning regimen
Description: 50% of the patients will receive Fludarabine + cyclophosphamide (F-araA 120 mg/m2 total dose for 3 days (d-3,-2,-1) over 1 h infusion and cyclophosphamide 25 mg/kg/d (d-5 to d-2) for 4 days over 1-h infusion prior to hematopoietic cell transplantation , then post transplant cyclophosphamide dose 50 mg/kg on days +3 and +4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD Prophylaxis
Description: Cyclosporine A (CsA 3 mg/kg) start day +5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD Prophylaxis
Description: Cyclosporine A (CsA 3 mg/kg) start day +5

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogenic Stem Cell Transplantation
Description: using peripheral blood stem cells

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogenic Stem Cell Transplantation
Description: using peripheral blood stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG conditioning regimen
Description: the other 50% of the patients will receive Cyclophosphamide + ATG
Study: NCT01809795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry Smoothie
Study: NCT03862313

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-rtACS treatment
Description: For the sham-rtACS treatment arm, exactly the same medical device, setup, time schedule, etc. will be used as for the patients of the active-rtACS arm. However, sham-treated patients will receive no actual current stimulation during the therapy sessions.
Study: NCT02362360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Product
Description: A new 2-piece ostomy appliance developed by Coloplast A/S
Study: NCT01809795

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Smoothie
Study: NCT01504867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325mg loading dose once on study day 1, followed by 81mg dose once daily on study days 2-7. Administered by mouth or down nasal gastric tube.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose powder
Description: Matching lactose powder filled capsules will be administered on days 1-7.
Study: NCT01736813

Intervention type: DRUG
Intervention: Maraviroc
Description: Twelve patients with 300 mg/bid
Study: NCT02032472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of Arterial Pressure
Description: Pharmacies cooperate in measuring blood pressure of patients
Study: NCT03955393

Intervention type: OTHER
Intervention: 18F-FAZA PET IMAGING TECHNIQUE IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS
Description: 18F-FAZA is a highly selective PET radiotracer of hypoxia, which has been recently developed and tested in several studies (10-14). 18F-FAZA has been demonstrated to be a marker of hypoxia and pathological metabolic patterns which are common to all renal cancers.
Study: NCT02758587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: cross reference with arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: cross reference with arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: cross reference with arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: cross reference with arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: cross reference with arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: cross reference with arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: cross reference with arm/group descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: cross reference with arm/group descriptions
Study: NCT02529800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1402
Description: Tamsulosin HCl 0.4mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1402
Description: Tamsulosin HCl 0.4mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1402
Description: Tamsulosin HCl 0.4mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0412
Description: Tamsulosin HCl 0.2mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0412
Description: Tamsulosin HCl 0.2mg
Study: NCT02362360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coloplast Test Product
Description: A new 2-piece ostomy appliance developed by Coloplast A/S

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator (Hollister)
Description: Comparator is a Hollister FlexWear baseplate (ileostomy) or a Hollister SoftFlex baseplate (colostomy) both used with a Hollister open bag.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparator (Hollister)
Description: Comparator is a Hollister FlexWear baseplate (ileostomy) or a Hollister SoftFlex baseplate (colostomy) both used with a Hollister open bag.
Study: NCT02450201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyruvate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyruvate
Study: NCT02529800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0412
Description: Tamsulosin HCl 0.2mg
Study: NCT00914797

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled and oral terbutaline
Description: Inhalation of 2 mg terbutaline as powder as a single dosage. Oral terbutaline 10 mg as a single dosage.~Inhaled: Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076.~Oral: Tablet Bricanyl Retard 5 mg, MA no. 10954.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled and oral terbutaline
Description: Inhalation of 2 mg terbutaline as powder as a single dosage. Oral terbutaline 10 mg as a single dosage.~Inhaled: Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076.~Oral: Tablet Bricanyl Retard 5 mg, MA no. 10954.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: inhaled and oral terbutaline
Description: Inhalation of 2 mg terbutaline as powder as a single dosage. Oral terbutaline 10 mg as a single dosage.~Inhaled: Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076.~Oral: Tablet Bricanyl Retard 5 mg, MA no. 10954.
Study: NCT03376074

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated perfusion (HOPE)
Description: 25 patients: Application of HOPE for 2 hours, perfusion rate 100-150 ml/min, pressure controlled, perfusion pressure \< 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate solution (UWMP®), perfusate temperature 4-12 °C, perfusate oxygenation 40 KPa

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cold storage
Description: 75 patients transplanted in Rennes between 2010 and 2015 with a cold stored grafts, matched (ratio 1: 3) using a propensity score calculated according to some parameters
Study: NCT03187054

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior or posterior colporrhaphy
Description: will be performed in a traditional manner with midline plication of the fibromuscular layer using 2-0 delayed absorbable sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: anterior or posterior colporrhaphy
Description: will be performed in a traditional manner with midline plication of the fibromuscular layer using 2-0 delayed absorbable sutures.
Study: NCT01675869

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive Training of Attention and Metacognition (ETAM)
Description: ETAM is an 8-week intervention involving weekly concurrent child (n=\~6 per group) and parent intervention groups. The ETAM groups will be 1 hour in length (except for the first session which will be 2 hours).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Attention Control is an 8-week intervention involving weekly concurrent child (n=\~6 per group) and parent groups that control for the effects of attention. The groups will be 1 hour in length (except for the first session which will be 2 hours).
Study: NCT02436395

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A (povidone-iodine wash the surgical incision)
Description: Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with povidone-iodine wash the surgical incision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group B (normal saline wash the surgical incision)
Description: Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with normal saline wash the surgical incision
Study: NCT03057288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fiducial markers placement
Description: The main objective of this study is to evaluate the feasibility of fiducial markers placement under EUS guidance for patients with esophageal or rectal cancer with an indication of radiotherapy
Study: NCT02914366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03028883

Intervention type: OTHER
Intervention: Dose adjustments
Description: Do higher doses of buprenorphine result in a higher rate of neonatal abstinence syndrome as compared to lower doses of buprenorphine
Study: NCT01783483

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SternaLock Blue closure system
Description: SternaLock Blue closure system is a primary closure system plate-based

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Suture Wire
Description: Closure system wire-based used to approximate the two halfs of the sternum following a median sternotomy.
Study: NCT01701778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caudal Dexmedetomidine
Description: Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg~Intravenous: 10 ml normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Dexmedetomidine
Description: Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: dexmedetomidine 1µg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Induction and maintain anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Induction and maintain anaesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sevoflurane
Description: Induction and maintain anaesthesia
Study: NCT04189419

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCM-AGH
Description: SCM-AGH will be administrated once a day for 3 days(D0, D1 and D2).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administrated once a day for 3 days(D0, D1 and D2).
Study: NCT00839020

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Navigated TKA with a minimally invasive approach
Description: Navigated total knee arthroplasty with a minimally invasive approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Navigated TKA with a conventional approach
Description: A navigated total knee arthroplasty is performed using the Orthopilot navigation system. A conventional approach is performed
Study: NCT01234688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
Study: NCT03906149

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Whole-body hyperthermia + standard medical care
Description: Whole-body hyperthermia will be applied two times during 4 weeks (week 0 and 2 after randomization) in addition to standard medical care. The hyperthermia will be applied using Heckel-HT3000 MPIIb. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical care
Description: Standard medical care included guideline-based anti-depressive drug treatment in combination with psychotherapy. During the 6 weeks of primary observation, the current medication should be maintained. The dose may be optimized with respect to clinical effectiveness and the reduction of side effects. The type of medication should not be changed during the 6 weeks. The use of additional somatic therapies such as sleep deprivation, light therapy, electroconvulsive therapy, or transcranial magnetic stimulation is not allowed.
Study: NCT03568825

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopatic Manual Therapy (OMT)
Description: OMT consisting of following interventions; thoracic spine and diaphragm mobilisation, traction of the cardia and posture correction.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopatic Manual Therapy (OMT)
Description: OMT consisting of following interventions; thoracic spine and diaphragm mobilisation, traction of the cardia and posture correction.
Study: NCT03575182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gait retraining program
Description: Supervised gait retraining with verbal and real-time visual feedback.
Study: NCT03836729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide/emtricitabine
Description: TAF/FTC will be available as 25/200 milligrams (mg) tablet. Subjects will be administered TAF/FTC 25/200 mg QD via the oral route.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254
Description: GSK3640254 will be available as 100 mg capsule. Subjects will be administered GSK3640254 200 mg capsule QD via the oral route.
Study: NCT02938910

Intervention type: OTHER
Intervention: non interventional study
Description: Non invasive imaging study without interventional procedures

Intervention type: OTHER
Intervention: non interventional study
Description: Non invasive imaging study without interventional procedures

Intervention type: OTHER
Intervention: non interventional study
Description: Non invasive imaging study without interventional procedures

Intervention type: OTHER
Intervention: non interventional study
Description: Non invasive imaging study without interventional procedures
Study: NCT02020733

Intervention type: DEVICE
Group type: OTHER
Intervention: Balloon catheter

Intervention type: DEVICE
Group type: OTHER
Intervention: metal cannula
Study: NCT05350683

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: In the 12 hours prior to surgery, the principal investigator performed the remote ischemic preconditioning (RIPC) following the protocol: 4 cycles of inflation/deflation of a pneumatic arterial tourniquet on the non-dominant upper extremity. Considering inflated a pressure of 50mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of deflation. Patients included in the preconditioning group were randomized at a rate of 1:1 consecutively.
Study: NCT01853007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COACH Program